Dataset Information

Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study.

ABSTRACT: (1) Aims: To assess the incidence of inflammatory bowel disease (IBD) in Spain, to describe the main epidemiological and clinical characteristics at diagnosis and the evolution of the disease, and to explore the use of drug treatments. (2) Methods: Prospective, population-based nationwide registry. Adult patients diagnosed with IBD-Crohn's disease (CD), ulcerative colitis (UC) or IBD unclassified (IBD-U)-during 2017 in Spain were included and were followed-up for 1 year. (3) Results: We identified 3611 incident cases of IBD diagnosed during 2017 in 108 hospitals covering over 22 million inhabitants. The overall incidence (cases/100,000 person-years) was 16 for IBD, 7.5 for CD, 8 for UC, and 0.5 for IBD-U; 53% of patients were male and median age was 43 years (interquartile range = 31-56 years). During a median 12-month follow-up, 34% of patients were treated with systemic steroids, 25% with immunomodulators, 15% with biologics and 5.6% underwent surgery. The percentage of patients under these treatments was significantly higher in CD than UC and IBD-U. Use of systemic steroids and biologics was significantly higher in hospitals with high resources. In total, 28% of patients were hospitalized (35% CD and 22% UC patients, p < 0.01). (4) Conclusion: The incidence of IBD in Spain is rather high and similar to that reported in Northern Europe. IBD patients require substantial therapeutic resources, which are greater in CD and in hospitals with high resources, and much higher than previously reported. One third of patients are hospitalized in the first year after diagnosis and a relevant proportion undergo surgery.

SUBMITTER: Chaparro M

PROVIDER: S-EPMC8268420 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study.

Chaparro María M Garre Ana A Núñez Ortiz Andrea A Diz-Lois Palomares María Teresa MT Rodríguez Cristina C Riestra Sabino S Vela Milagros M Benítez José Manuel JM Fernández Salgado Estela E Sánchez Rodríguez Eugenia E Hernández Vicent V Ferreiro-Iglesias Rocío R Ponferrada Díaz Ángel Á Barrio Jesús J Huguet José María JM Sicilia Beatriz B Martín-Arranz María Dolores MD Calvet Xavier X Ginard Daniel D Alonso-Abreu Inmaculada I Fernández-Salazar Luis L Varela Trastoy Pilar P Rivero Montserrat M Vera-Mendoza Isabel I Vega Pablo P Navarro Pablo P Sierra Mónica M Cabriada José Luis JL Aguas Mariam M Vicente Raquel R Navarro-Llavat Mercè M Echarri Ana A Gomollón Fernando F Guerra Del Río Elena E Piñero Concepción C Casanova María José MJ Spicakova Katerina K Ortiz de Zarate Jone J Torrella Cortés Emilio E Gutiérrez Ana A Alonso-Galán Horacio H Hernández-Martínez Álvaro Á Marrero José Miguel JM Lorente Poyatos Rufo R Calafat Margalida M Martí Romero Lidia L Robledo Pilar P Bosch Orencio O Jiménez Nuria N Esteve Comas María M Duque José María JM Fuentes Coronel Ana María AM Josefa Sampedro Manuela M Sesé Abizanda Eva E Herreros Martínez Belén B Pozzati Liliana L Fernández Rosáenz Hipólito H Crespo Suarez Belén B López Serrano Pilar P Lucendo Alfredo J AJ Muñoz Vicente Margarita M Bermejo Fernando F Ramírez Palanca José Joaquín JJ Menacho Margarita M Carmona Amalia A Camargo Raquel R Torra Alsina Sandra S Maroto Nuria N Nerín de la Puerta Juan J Castro Elena E Marín-Jiménez Ignacio I Botella Belén B Sapiña Amparo A Cruz Noelia N Forcelledo José Luis F JLF Bouhmidi Abdel A Castaño-Milla Carlos C Opio Verónica V Nicolás Isabel I Kutz Marcos M Abraldes Bechiarelli Alfredo A Gordillo Jordi J Ber Yolanda Y Torres Domínguez Yolanda Y Novella Durán María Teresa MT Rodríguez Mondéjar Silvia S Martínez-Cerezo Francisco J FJ Kolle Lilyan L Sabat Miriam M Ledezma Cesar C Iyo Eduardo E Roncero Óscar Ó Irisarri Rebeca R Lluis Laia L Blázquez Gómez Isabel I Zapata Eva María EM José Alcalá María M Martínez Pascual Cristina C Montealegre María M Mata Laura L Monrobel Ana A Hernández Camba Alejandro A Hernández Luis L Tejada María M Mir Alberto A Galve María Luisa ML Soler Marta M Hervías Daniel D Gómez-Valero José Antonio JA Barreiro-de Acosta Manuel M Rodríguez-Artalejo Fernando F García-Esquinas Esther E Gisbert Javier P JP

Journal of clinical medicine 20210629 13

(1) Aims: To assess the incidence of inflammatory bowel disease (IBD) in Spain, to describe the main epidemiological and clinical characteristics at diagnosis and the evolution of the disease, and to explore the use of drug treatments. (2) Methods: Prospective, population-based nationwide registry. Adult patients diagnosed with IBD-Crohn's disease (CD), ulcerative colitis (UC) or IBD unclassified (IBD-U)-during 2017 in Spain were included and were followed-up for 1 year. (3) Results: We identifi ...[more]

PMID: 34209680

Similar Datasets

Project description:Background and aimsThe objective of this study was to evaluate the risk of colorectal cancer (CRC) in patients taking aminosalicylates (5-ASA) for inflammatory bowel disease (IBD).MethodsThe General Practice Research Database (GPRD) which contains the primary care records of five million people in the UK was used to identify users of mesalazine, balsalazide, olsalazine, or sulfasalazine with a history of IBD. In a nested case control analysis, each incident CRC case with any use of a 5-ASA in the six months before the CRC diagnosis was matched by age, sex, and calendar time to six control patients who were also currently using a 5-ASA. Patients were then classified according to regularity of use. The analysis was controlled for body mass index, IBD duration, history of colorectal polyps, use of non-steroidal anti-inflammatory drugs, paracetamol, aspirin, immunosuppressants, oral and rectal glucocorticoids, prior gastrointestinal hospitalisation, recorded colonoscopy, and number of visits to the general practitioner for IBD symptoms in the 6-24 months before diagnosis.ResultsThe study population included 18 969 patients, of whom 100 had developed CRC during 5-ASA exposure. Most of these cases had a history of ulcerative colitis (76 patients). In the case control analysis, regular users, defined as having six or more 5-ASA prescriptions in the previous 12 months, were found to have a decreased risk of CRC compared with irregular users (crude odds ratio (OR) 0.7 (0.44-1.03); adjusted OR 0.60 (0.38-0.96)). Regular users of sulfasalazine with 6-12 prescriptions before had an adjusted OR of 0.95 (0.22-4.11); with 13-30 prior prescriptions this was 0.41 (0.14-1.20) and with >30 prior prescriptions this was 0.77 (0.37-1.60). For mesalazine users, these values were 1.13 (0.49-2.59), 0.30 (0.11-0.83), and 0.31 (0.11-0.84), respectively.ConclusionThese results show that regular 5-ASA use is associated with some reduction in the risk of CRC developing in ulcerative colitis.

Project description:BACKGROUND:Nephrotic syndrome (NS) is one of the most frequent occurring chronic kidney diseases in childhood, despite its rarely occurrence in the general population. Detailed information about clinical data of NS (e.g. average length of stay, complications) as well as of secondary nephrotic syndrome (SNS) is not well known. METHODS:A nationwide ESPED follow-up study presenting the clinical course and management of children with NS in Germany. RESULTS:In course of 2 years, 347 children developed the first onset of NS, hereof 326 patients (93.9%) had a primary NS, and 19 patients had a SNS (missing data in 2 cases), the majority due to a Henoch-Schönlein Purpura. Patients with steroid-resistant NS (SRNS) stayed significantly longer in hospital than children with steroid-sensitive NS (25.2 vs. 13.3 d, p < 0.001). Patients with bacterial/viral infections stayed longer in hospital (24.9 d/19.5d) than children without an infection (14.2 d/14.9 d; p < 0.001; p = 0.016). Additionally, children with urinary tract infections (UTI) (p < 0,001), arterial hypertension (AH) (p < 0.001) and acute renal failure (ARF) (p < 0,001) stayed significantly longer in hospital. Patients with SRNS had frequent complications (p = 0.004), such as bacterial infections (p = 0.013), AH (p < 0.001), UTI (p < 0.001) and ARF (p = 0.007). Children with a focal segmental glomerulosclerosis (FSGS) had significantly more complications (p = 0.04); specifically bacterial infections (p = 0.01), UTI (p = 0.003) and AH (p < 0,001). Steroid-resistance was more common in patients with UTI (p < 0.001) and in patients with ARF (p = 0.007). Furthermore, steroid-resistance (p < 0.001) and FSGS (p < 0.001) were more common in patients with AH. CONCLUSIONS:This nationwide, largest German study presents results on the clinical course of children with NS considering a diverse range of complications that can occur with NS. The establishment of a region-wide and international pediatric NS register would be useful to conduct further diagnostic and therapy studies with the aim to reduce the complication rate and to improve the prognosis of NS, and to compare the data with international cohorts.

Dataset Information

Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study.

Publications

Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets